Seong-Ho Park
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Year:
2026
Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this study, we show that HNSCC relies on elevated glucose transporter 1 (GLUT1)–mediated glucose uptake to support redox homeostasis and tumor growth. Analyses of GLUT1 expression data in tumors and cancer cell lines reveal significant upregulation of GLUT1 in HNSCC relative to both normal tissue and other cancer subtypes and that high GLUT1 expression correlates with poorer clinical outcomes. Using a basal epithelial layer–specific GLUT1-knockout mouse model, we demonstrate that GLUT1 ablation in HNSCC cells of origin markedly attenuates tumor initiation and progression, implicating the necessity of GLUT1 in HNSCC tumorigenesis. Building on this observation, combining pharmacologic inhibition of GLUT1 with pro-oxidants such as vitamin C and auranofin induces potent cytotoxicity in vitro and in vivo, partly by precipitating oxidative stress. We further observe that insulin signaling is required to sustain glucose uptake and redox homeostasis, as insulin receptor knockdown decreases proliferation and increases reactive oxygen species levels. Together, these results suggest that although GLUT1 overexpression is a key driver of glucose uptake, insulin signaling also contributes to the metabolic and oncogenic pathways underlying HNSCC progression. Consequently, strategies that co-target GLUT1 and insulin signaling to restrict glucose flux may synergize with pro-oxidant therapies, offering a promising therapeutic avenue for HNSCC. Significance: Enhanced GLUT1 expression and oncogenic insulin signaling drive elevated glucose uptake in HNSCC, which contribute to the maintenance of redox homeostasis and tumor growth. Disrupting both glucose uptake and redox balance may offer a promising therapeutic approach.
Year:
2025
Background: This study aimed to infer a causal gene network associated with bone metastasis in lung cancer and to validate its reliability through experimental gene expression analysis.Methods: Using DNA microarray data from the Gene Expression Omnibus, we analyzed samples from primary lung cancer and those with bone metastasis. Commonly expressed genes in both groups were identified, and a causal network was inferred using Bayesian network inference with Java Objects based on the Bayesian Dirichlet score. To evaluate the network, we predicted the expression changes of downstream genes following knockdown of a key upstream gene and compared these predictions with mRNA expression levels in fatty acid desaturase 1 (FADS1)-knockdown lung cancer cells.Results: The genes FADS1, cardiotrophin-like cytokine factor 1 (CLCF1), chromosome 4 open reading frame 48, sushi, nidogen and EGF like domains 1, FK506-binding protein 15, and coenzyme Q10A (COQ10A) were identified as directly associated with lung cancer bone metastasis. Among them, FADS1 appeared to have a regulatory role, influencing downstream targets. Notably, CLCF1 and COQ10A showed significantly increased expression in FADS1-knockdown cells, consistent with the network’s predictions.Conclusions: These findings suggest that Bayesian network analysis is a reliable machine learning approach for uncovering causal gene relationships in cancer metastasis. Furthermore, FADS1 may serve as a potential therapeutic target in lung cancer bone metastasis. The validity of this network was supported by in vitro experiments using a lung cancer cell line.
Year:
2025
Year:
2025
Dysregulated insulin signaling reduces HNSCC tumor growth. A, Plasma insulin concentration of vehicle- or STZ-treated mice (40 mg/kg i.p. for 5 consecutive days; n = 4 for each group). Two-tailed t test. *, P B, Representative H&E staining of pancreatic tissues collected from vehicle- or STZ-treated mice. Dashed lines denote individual pancreatic islets. Scale bars, 1 mm. C, Intraperitoneal glucose tolerance test of vehicle- and STZ-treated mice ( n = 4 for each group). D, In vivo tumor growth of FaDu xenograft tumors in vehicle-treated ( n = 4) and STZ-treated ( n = 4) mice. Two-way ANOVA. ****, P E, H&E and IHC analyses of pH2A.X, 4HNE, and Ki67 in FaDu xenograft tumors collected from vehicle- and STZ-treated mice. Scale bars, 1 mm. F, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and Ki67 (nuclear/cell proliferation marker) in xenografted tumors. Four to six images of each tumor were captured and analyzed for quantification ( n = 4 for each group). Two-tailed t test, **, P P
Year:
2025
Auranofin induces cytotoxicity as a pro-oxidant in HNSCC. A and B, In vitro proliferation (top) and intracellular H 2 O 2 levels (bottom) of FaDu ( A ) or SCC-61 ( B ) cells treated with vehicle, WZB117 (20 μmol/L), auranofin (1 μmol/L), or combination of WZB117 and auranofin ( n = 6 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P P P C–F, In vivo tumor growth ( C ), tumor weights ( D ), images of individual tumors ( E ), and IHC analysis of GLUT1, pH2A.X, 4HNE, and CC3 ( F ) in SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6) or auranofin (10 mg/kg i.p. daily; n = 6). Two-way ANOVA for tumor growth ( C ) and two-tailed t test for tumor weight ( D ). ****, P P G, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and CC3 (apoptotic cell marker) in xenografted tumors ( n = 6 for each group). Four to six images of each tumor were captured and analyzed for quantification. Two-tailed t test. **, P H, In vivo tumor growth of FaDu xenograft tumors treated with vehicle PBS/DMSO ( n = 16), WZB117 (20 mg/kg i.p. daily; n = 16), auranofin (10 mg/kg i.p. daily; n = 15), or combination of WZB117 and auranofin ( n = 12). Two-way ANOVA. ****, P P P I, In vivo tumor growth of SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6), WZB117 (20 mg/kg i.p. daily; n = 7), auranofin (10 mg/kg i.p. daily; n = 7), or combination of WZB117 and auranofin ( n = 7). Two-way ANOVA. ****, P P P
Year:
2025
GLUT1 ablation attenuates tumorigenesis in 4NQO-induced mouse model of human HNSCC. A, Schematic showing timeline for treatment of mice with 4NQO. 4NQO was administered in drinking water for 8 weeks and replaced with normal drinking water for the remainder of the study. Tongues were collected every 2 weeks after the first exposure to 4NQO for analyses. For Cre-mediated GLUT1 ablation in basal epithelial cells, tamoxifen was injected (100 mg/kg i.p. daily for 5 consecutive days) 4 weeks after the final administration of 4NQO. Tumors were harvested 4 weeks after the final tamoxifen injection. B, Representative IHC analyses of GLUT1 expression in CK5 + and p63 + basal epithelial cells of untreated and 4NQO-treated mice. C, Representative images of tumor-bearing tongues from 4NQO-treated mice; black arrowheads depict squamous tongue tumors (left). Graph shows quantification of the number of visible tongue tumors identified in 4NQO-treated WT and Krt5 + basal epithelial–specific GLUT1 CKO mice ( n = 6 for each group). Mann–Whitney U test. P = 0.06 (right). D, Representative H&E images of 4NQO-treated WT and CKO mouse tongues. Arrows depict 4NQO-induced squamous tumors (left). Graph shows quantification of 4NQO-induced tongue tumor area (μm 2 ) in GLUT1 WT and CKO mice ( n = 6 for each group). Mann–Whitney U test. **, P E, Representative co-immunofluorescent staining of GLUT1 and p63 in 4NQO-induced squamous tongue tumors of GLUT1 WT and GLUT1 CKO mice. DAPI, 4',6-diamidino-2-phenylindole. F, Representative IHC analyses of p63, GLUT1, and Ki67 expression in 4NQO-induced squamous tongue tumors. All error bars represent mean ± SEM. All scale bars, 1 mm unless otherwise noted. H&E, hematoxylin and eosin; KO, knockout.
Year:
2025
Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this study, we show that HNSCC relies on elevated glucose transporter 1 (GLUT1)–mediated glucose uptake to support redox homeostasis and tumor growth. Analyses of GLUT1 expression data in tumors and cancer cell lines reveal significant upregulation of GLUT1 in HNSCC relative to both normal tissue and other cancer subtypes and that high GLUT1 expression correlates with poorer clinical outcomes. Using a basal epithelial layer–specific GLUT1-knockout mouse model, we demonstrate that GLUT1 ablation in HNSCC cells of origin markedly attenuates tumor initiation and progression, implicating the necessity of GLUT1 in HNSCC tumorigenesis. Building on this observation, combining pharmacologic inhibition of GLUT1 with pro-oxidants such as vitamin C and auranofin induces potent cytotoxicity in vitro and in vivo , partly by precipitating oxidative stress. We further observe that insulin signaling is required to sustain glucose uptake and redox homeostasis, as insulin receptor knockdown decreases proliferation and increases reactive oxygen species levels. Together, these results suggest that although GLUT1 overexpression is a key driver of glucose uptake, insulin signaling also contributes to the metabolic and oncogenic pathways underlying HNSCC progression. Consequently, strategies that co-target GLUT1 and insulin signaling to restrict glucose flux may synergize with pro-oxidant therapies, offering a promising therapeutic avenue for HNSCC. Significance: Enhanced GLUT1 expression and oncogenic insulin signaling drive elevated glucose uptake in HNSCC, which contribute to the maintenance of redox homeostasis and tumor growth. Disrupting both glucose uptake and redox balance may offer a promising therapeutic approach.
Year:
2025
Insulin signaling promotes glucose-mediated antioxidative capacities in HNSCC. A, In vitro proliferation of FaDu cells in 25 mmol/L glucose media treated with or without 5 ng/mL insulin ( n = 4 for each group). Two-way ANOVA. ****, P B, Immunoblot analysis of pAKT and total AKT expression in FaDu cells treated with 20 ng/mL insulin over a time period of 0–120 minutes. C and D, Relative glucose uptake ( C ) and intracellular ROS measurement ( D ) in FaDu cells treated with 20 ng/mL insulin in 25 or 5 mmol/L glucose conditions ( n = 3 for each group). Two-tailed t test. ****, P P P E, In vitro proliferation of shScr, shINSR, or shINSR + 5 mmol/L NAC FaDu cells ( n = 4 for each group). Two-way ANOVA. **, P F, Immunoblot analyses of shScr and shINSR FaDu cells. β-Actin was used as the loading control. G and H, Relative glucose uptake ( G ) and intracellular ROS levels ( H ) in shScr and shINSR FaDu cells ( n = 3). Two-tailed t test. ****, P P I and J, In vitro proliferation of shScr, oncogenic mutant AKT E17K and PIK3CA H1047L expressing FaDu cells grown in 5 or 25 mmol/L glucose media ( n = 4 for each group). Two-way ANOVA. ****, P K, Immunoblot analysis of pAKT, AKT, pS6, S6, p4EBP1, and 4EBP1 expression in shScr and mutant AKT E17K and PIK3CA H1047L FaDu cells. L, Relative cellular glucose uptake and intracellular H 2 O 2 levels in FaDu PIK3CA H1047L mutant cells cultured in 5 or 25 mmol/L glucose ( n = 3 for each group). Two-tailed t test. ***, P M, Relative cellular glucose uptake and intracellular H 2 O 2 levels in FaDu AKT E17K mutant cells cultured in 5 or 25 mmol/L glucose ( n = 3 for each group). Two-tailed t test. *, P
Year:
2025
Combination of GLUT1 inhibition and ascorbate suppresses HNSCC tumor growth. A and B, In vitro proliferation (top) and intracellular H 2 O 2 levels (bottom) of FaDu ( A ) or SCC-61 ( B ) cells treated with WZB117 (20 μmol/L) or BAY-876 (100 nmol/L) and vitamin C (0.25 mmol/L) or combination of GLUT1 inhibitor and vitamin C ( n = 5 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P P P P C, In vivo tumor growth of FaDu xenografts treated with vehicle PBS/DMSO, WZB117 (20 mg/kg i.p. daily), or BAY-876 (4.5 mg/kg of corn oil/DMSO p.o. daily; n = 6 for each group). Two-way ANOVA. ****, P D, In vivo tumor growth of FaDu xenograft tumors treated with vehicle PBS/DMSO ( n = 16), WZB117 (20 mg/kg i.p. daily; n = 16), vitamin C (4 g/kg i.p. daily; n = 7), and a combination of WZB117 and vitamin C ( n = 7). Two-way ANOVA. ****, P P P E–G, In vivo tumor growth of SCC-61 xenografts ( E ), tumor weights ( F ), IHC analysis of 4HNE, Ki67, and pH2A.X ( G ) in SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6), WZB117 (20 mg/kg i.p. daily; n = 5), vitamin C (4 g/kg i.p. daily; n = 5), or combination of WZB117 and vitamin C ( n = 6). Two-way ANOVA. **, P P H, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and Ki67 (nuclear/cell proliferation marker) in xenografted tumors. Four to six images of each tumor were captured and analyzed for quantification. Two-tailed t test. *, P
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Collaborators (12)
Tae Gyu Oh
Assistant Professor
University of Oklahoma Health Sciences Center
Junho Hur
Associate Professor
Hanyang University
Jung-whan Kim
Associate Professor
University of Oklahoma
Pankaj Singh
Professor and Chair
University of Oklahoma Health Sciences Center
Sung Bae Park
Seoul National University College of Medicine
Chul‐Ho Kim
Ajou University
Dinesh Thotala
Associate Professor
University of Oklahoma Health Sciences Center
Hoon Hur
Professor
Ajou University
MinJeong Kim
Kyunghee University
Jiyoung Lee
George Washington University
Tae Hoon Kim
Professor
University of Texas at Dallas
Ji Yun Jeong
Sungkyunkwan University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.